Literatur
- 1
Courtney M G, Nunes D P, Bergin C F. et al .
Colonoscopic but not histological appearances determine liklyhood of relapse of ulcerative
colitis.
Am J Gastroenterol.
1991;
86
243 (III)
- 2
Goodman M W, Eberle D E, Kuchler L A. et al .
Microscopic activity predicts relapse in patients with distal ulcerative colitis on
4-Aminosalizylate enemas.
Gastroenterology.
1988;
96 (Suppl)
A151 (III)
- 3
Riley S A, Mani V, Goodman M J. et al .
Microscopic activity in ulcerative colitis: what does it mean?.
Gut.
1991;
32
174-178 (IIa)
- 4
Ardizzone S, Petrillo M, Imbesi V. et al .
Is maintenance therapy always necessary for patients with ulcerative colitis in remission?.
Aliment Pharmacol Ther.
1999;
13
373-379 (Ib)
- 5
Kornbluth A A, Salomon P, Sacks H S. et al .
Meta-analysis of the effectiveness of current drug therapy of ulcerative colitis.
J Clin Gastroenterol.
1993;
16
215-218 (Ia)
- 6
Sutherland L RD, Beck P.
Alternatives to Sulfasalazine: A meta-analysis of 5-ASA in the treatment of ulcerative
colitis.
Inflamm Bowel Dis.
1997;
65-78 (Ia)
- 7
Sutherland L R, May G R, Shaffer E A.
Sulfasalazine revisited: a meta-analysis of 5-aminosalicylic acid in the treatment
of ulcerative colitis.
Ann Intern Med.
1993;
118
540-549 (Ia)
- 8
Marshall J K, Irvine E J.
Rectal Aminosalizylate therapy for distal ulcerative colitis: a meta-analysis.
Aliment Pharmacol Ther.
1995;
9
293-300 (Ia)
- 9
d’Albasio G, Pacini F, Camarri E. et al .
Combined therapy with 5-aminosalicylic acid tablets and enemas for maintaining remission
in ulcerative colitis: a randomized double-blind study.
Am J Gastroenterol.
1997;
92
1143-1147 (Ib)
- 10
Riley S A.
What dose of 5-aminosalicylic acid (mesalazine) in ulcerative colitis?.
Gut.
1998;
42
761-763 (IV)
- 11
Azad K han AK, Howes D T, Piris J. et al .
Optimum dose of sulphasalazine for maintenance treatment in ulcerative colitis.
Gut.
1980;
21
232-240 (Ib)
- 12
Fockens P, Mulder C J, Tytgat G N. et al .
Comparison of the efficacy and safety of 1.5 compared with 3.0 g oral slow-release
mesalazine (Pentasa) in the maintenance treatment of ulcerative colitis. Dutch Pentasa
Study Group.
Eur J Gastroenterol Hepatol.
1995;
7
1025-1030 (Ib)
- 13
Kiilerich S, Ladefoged K, Rannem T. et al .
Prophylactic effects of olsalazine v sulphasalazine during 12 months maintenance treatment
of ulcerative colitis. The Danish Olsalazine Study Group.
Gut.
1992;
33
252-255 (Ib)
- 14
Biddle W L, Greenberger N J, Swan J T. et al .
5-Aminosalicylic acid enemas: effective agent in maintaining remission in left-sided
ulcerative colitis.
Gastroenterology.
1988;
94
1075-1079 (Ib)
- 15
Mantzaris G J, Hatzis A, Petraki K. et al .
Intermittent therapy with high-dose 5-aminosalicylic acid enemas maintains remission
in ulcerative proctitis and proctosigmoiditis.
Dis Colon Rectum.
1994;
37
58-62 (Ib)
- 16
d’Albasio G, Trallori G, Ghetti A. et al .
Intermittent therapy with high-dose 5-aminosalicylic acid enemas for maintaining remission
in ulcerative proctosigmoiditis.
Dis Colon Rectum.
1990;
33
394-397 (Ib)
- 17
d’Albasio G, Paoluzi P, Campieri M. et al .
Maintenance treatment of ulcerative proctitis with mesalazine suppositories: a double-blind
placebo-controlled trial. The Italian IBD Study Group.
Am J Gastroenterol.
1998;
93
799-803 (Ib)
- 18
Marteau P, Crand J, Foucault M. et al .
Use of mesalazine slow release suppositories 1 g three times per week to maintain
remission of ulcerative proctitis: a randomised double blind placebo controlled multicentre
study.
Gut.
1998;
42
195-199 (Ib)
- 19
Carbonnel F, Boruchowicz A, Duclos B. et al .
Intravenous cyclosporine in attacks of ulcerative colitis: short-term and long-term
responses.
Dig Dis Sci.
1996;
41
2471-2476 (III)
- 20
Campbell S, Ghosh S.
Combination immunomodulatory therapy with cyclosporine and azathioprine in corticosteroid-resistant
severe ulcerative colitis: the Edinburgh experience of outcome.
Dig Liver Dis.
2003;
35
546-551 (III)
- 21
Cohen R D, Stein R, Hanauer S B.
Intravenous cyclosporin in ulcerative colitis: a five-year experience.
Am J Gastroenterol.
1999;
94
1587-1592 (III)
- 22
Cohen R D, Woseth D M, Thisted R A. et al .
A meta-analysis and overview of the literature on treatment options for left-sided
ulcerative colitis and ulcerative proctitis.
Am J Gastroenterol.
2000;
95
1263-1276 (Ia)
- 23
Kruis W, Schreiber S, Theuer D. et al .
Low dose balsalazide (1.5 g twice daily) and mesalazine (0.5 g three times daily)
maintained remission of ulcerative colitis but high dose balsalazide (3.0 g twice
daily) was superior in preventing relapses.
Gut.
2001;
49
783-789 (Ib)
- 24
Sandborn W J.
Azathioprine: state of the art in inflammatory bowel disease.
Scand J Gastroenterol Suppl.
1998;
225
92-99 (IV)
- 25
Lindgren S, Lofberg R, Bergholm L. et al .
Effect of budesonide enema on remission and relapse rate in distal ulcerative colitis
and proctitis.
Scand J Gastroenterol.
2002;
37
705-710 (Ib)
- 26
Meyers S, Lerer P K, Feuer E J. et al .
Predicting the outcome of corticoid therapy for acute ulcerative colitis. Results
of a prospective, randomized, double-blind clinical trial.
J Clin Gastroenterol.
1987;
9
50-54 (Ib)
- 27
Kruis W, Schutz E, Fric P. et al .
Double-blind comparison of an oral Escherichia coli preparation and mesalazine in
maintaining remission of ulcerative colitis.
Aliment Pharmacol Ther.
1997;
11
853-858 (Ib)
- 28
Rembacken B J, Snelling A M, Hawkey P M. et al .
Non-pathogenic Escherichia coli versus mesalazine for the treatment of ulcerative
colitis: a randomised trial.
Lancet.
1999;
354
635-639 (Ib)
- 29
Kruis W, Fric P, Pokrotnieks J. et al .
Maintaining remission of ulcerative colitis with the probiotic E. coli Nissle 1917
is as effective as with standard mesalazine.
Gut.
2004 (in press) (Ib);
- 30
Fernandez-Banares F, Hinojosa J, Sanchez-Lombrana J L. et al .
Randomized clinical trial of Plantago ovata seeds (dietary fiber) as compared with
mesalamine in maintaining remission in ulcerative colitis. Spanish Group for the Study
of Crohn’s Disease and Ulcerative Colitis (GETECCU).
Am J Gastroenterol.
1999;
94
427-433 (Ib)
- 31
Pinczowski D, Ekbom A, Baron J. et al .
Risk factors for colorectal cancer in patients with ulcerative colitis: a case-control
study.
Gastroenterology.
1994;
107
117-120 (III)
- 32
Moody G A, Jayanthi V, Probert C S. et al .
Long-term therapy with sulphasalazine protects against colorectal cancer in ulcerative
colitis: a retrospective study of colorectal cancer risk and compliance with treatment
in Leicestershire.
Eur J Gastroenterol Hepatol.
1996;
8
1179-1183 (IIb)
- 33
Eaden J, Abrams K, Ekbom A. et al .
Colorectal cancer prevention in ulcerative colitis: a case-control study.
Aliment Pharmacol Ther.
2000;
14
145-153 (III)
Prof. Dr. W. Kruis
Evangelisches Krankenhaus Köln-Kalk, Abt. Innere Medizin
Buchforststraße 2
51103 Köln
Telefon: ++ 49/02 21/82 89-52 89
Fax: ++ 49/02 21/82 89-52 91
eMail: kruis@evkk.de
